Related references
Note: Only part of the references are listed.Implication of the Toll-Like Receptor 4 Pathway in the Response to Interferon-β in Multiple Sclerosis
Marta F. Bustamante et al.
ANNALS OF NEUROLOGY (2011)
The IL-17 pathway as a major therapeutic target in autoimmune diseases
Yan Hu et al.
YEAR IN IMMUNOLOGY (2011)
Loss of Braking Signals During Inflammation A Factor Affecting the Development and Disease Course of Multiple Sclerosis
Francesca Gilli et al.
ARCHIVES OF NEUROLOGY (2011)
Classical immunomodulatory therapy in multiple sclerosis How it acts, how it works
Amelia Mendes et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2011)
Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?
D. Hesse et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: Prospective clinical and MRI follow-up study
Sanna Hagman et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Biomarkers of disease activity in multiple sclerosis
Jerome J. Graber et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Mohsen Khademi et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer et al.
NATURE (2011)
Determinants of interferon β efficacy in patients with multiple sclerosis
Joep Killestein et al.
NATURE REVIEWS NEUROLOGY (2011)
Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple Sclerosis
Richard A. Rudick et al.
PLOS ONE (2011)
Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy
Robert H. Goertsches et al.
PHARMACOGENOMICS (2011)
Systematic review of genome-wide expression studies in multiple sclerosis
A. K. Kemppinen et al.
BMJ OPEN (2011)
Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis
P. Serrano-Fernandez et al.
AUTOIMMUNITY (2010)
Therapy of MS
Reza Vosoughi et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2010)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis
Kaushal S. Gandhi et al.
HUMAN MOLECULAR GENETICS (2010)
T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis
Robert C. Axtell et al.
NATURE MEDICINE (2010)
Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosis
Anat Achiron et al.
NEUROBIOLOGY OF DISEASE (2010)
Breakthrough disease during interferon-β therapy in MS No signs of impaired biologic response
D. Hesse et al.
NEUROLOGY (2010)
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS
L. F. van der Voort et al.
NEUROLOGY (2010)
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-β-1b treatment in relapsing remitting MS
Robert H. Goertsches et al.
PHARMACOGENOMICS (2010)
IFN-β pharmacogenomics in multiple sclerosis
Koen Vandenbroeck et al.
PHARMACOGENOMICS (2010)
IL-17RC: a partner in IL-17 signaling and beyond
Allen W. Ho et al.
SEMINARS IN IMMUNOPATHOLOGY (2010)
Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells
Michael Gurevich et al.
BMC MEDICAL GENOMICS (2009)
A gene signature for post-infectious chronic fatigue syndrome
John W. Gow et al.
BMC MEDICAL GENOMICS (2009)
Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
Emilia Sbardella et al.
BMC NEUROLOGY (2009)
A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis
M. Comabella et al.
BRAIN (2009)
IL-1/IL-1ra balance in the brain revisited - Evidence from transgenic mouse models
S. Spulber et al.
BRAIN BEHAVIOR AND IMMUNITY (2009)
Expression of TH1 and TH17 cytokines and transcription factors in multiple sclerosis patients: Does baseline T-Bet mRNA predict the response to interferon-beta treatment?
Jelena Drulovic et al.
JOURNAL OF NEUROIMMUNOLOGY (2009)
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis
Richard A. Rudick et al.
LANCET NEUROLOGY (2009)
Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event
M. S. Freedman et al.
MULTIPLE SCLEROSIS (2009)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
Philip L. De Jager et al.
NATURE GENETICS (2009)
Demyelinating events in early multiple sclerosis have inherent severity and recovery
E. M. Mowry et al.
NEUROLOGY (2009)
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis
Danielle Burger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The Orphan G Protein-Coupled Receptor 3 Modulates Amyloid-Beta Peptide Generation in Neurons
Amantha Thathiah et al.
SCIENCE (2009)
Structure and signalling in the IL-17 receptor family
Sarah L. Gaffen
NATURE REVIEWS IMMUNOLOGY (2009)
Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis
L. K. Fisniku et al.
BRAIN (2008)
Natural history of multiple sclerosis in a population-based cohort
M. Debouverie et al.
EUROPEAN JOURNAL OF NEUROLOGY (2008)
Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients
Bianca Weinstock-Guttman et al.
JOURNAL OF NEUROIMMUNOLOGY (2008)
Monitoring of multiple sclerosis immunotherapy From single candidates to biomarker networks
Robert H. Goertsches et al.
JOURNAL OF NEUROLOGY (2008)
Predictive markers for response to interferon therapy in patients with multiple sclerosis
S. Malucchi et al.
NEUROLOGY (2008)
Pharmacogenomics of Interferon-β Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients
Lisa G. M. van Baarsen et al.
PLOS ONE (2008)
Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
Dirk Koczan et al.
ARTHRITIS RESEARCH & THERAPY (2008)
IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR(+) CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood
Saloua Zrioual et al.
JOURNAL OF IMMUNOLOGY (2008)
An extremes of outcome strategy provides evidence that multiple sclerosis is determined by alleles at the HLA-DRB1 locus
G. C. DeLuca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Novel definition files for human GeneChips based on GeneAnnot
Francesco Ferrari et al.
BMC BIOINFORMATICS (2007)
Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F
Rolf E. Kuestner et al.
JOURNAL OF IMMUNOLOGY (2007)
MRI in multiple sclerosis: What's inside the toolbox?
Mohit Neema et al.
NEUROTHERAPEUTICS (2007)
Zinc-ion binding and cytokine activity regutation pathways predicts outcome in retapsing-remitting muttipte scierosis
A. Achiron et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy
M. K. Singh et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2007)
Genome-wide network analysis reveals the global properties of IFN-β immediate transcriptional effects in humans
Guy Haskin Fernald et al.
JOURNAL OF IMMUNOLOGY (2007)
Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth
Shigeru Tanaka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response
Jerome J. Graber et al.
JOURNAL OF NEUROIMMUNOLOGY (2007)
HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice
R. Furlan et al.
GENE THERAPY (2007)
Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years
L. Lopatinskaya et al.
MULTIPLE SCLEROSIS (2006)
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis - A systematic review
Annette Langer-Gould et al.
ARCHIVES OF NEUROLOGY (2006)
The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients
Halina Bartosik-Psujek et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2006)
Baseline MRI predicts future attacks and disability in clinically isolated syndromes
M. Tintore et al.
NEUROLOGY (2006)
Signal transduction of sphingosine-1-phosphate G protein-coupled receptors
Nicholas Young et al.
THESCIENTIFICWORLDJOURNAL (2006)
T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients
Jun-ichi Satoh et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS
M Soilu-Hänninen et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis
M Caggiula et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2005)
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS
MJ Eikelenboom et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Transcription-based prediction of response to IFN beta using supervised computational methods
SE Baranzini et al.
PLOS BIOLOGY (2005)
Novel clusters of receptors for sphingosine-1 phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: New receptors for old ligands
E Kostenis
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients
MHJ Vogt et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis
KP Wandinger et al.
LANCET (2003)
Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis
S Stürzebecher et al.
BRAIN (2003)
Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis
LM Villar et al.
ANNALS OF NEUROLOGY (2003)
Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors
K Uhlenbrock et al.
CELLULAR SIGNALLING (2002)
Soluble and transmembrane Isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer
D Haudenschild et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
